Targeting Effect Study of ￣(3) H-Mitoxantrone Nanosphereson Hepatocellular Carcinoma(HCC) Model in Nude Mice

The distribution of ￣(3)H-mitoxantrone polybutyl cyanoacrylate nanospheres(￣(3)H-DHAQ-PBCA-NS)in the viscera,muscle and tumors of human hepatocellular carcinoma (HCC)model in nude mice was studied with liquid scintillation counting techniique. The results showed that the ￣(3)H-DHAQ-PBCA-NS had remarkable liver targeting effect. The content of ￣(3)H-DHAQ-PBCA-NSin liver and heterotopic liver tumor was found to be 71.31±10. 49% of total amount of drug in animal body. It was also found that the content of ￣(3)H-DHAQ-PBCA-NS in liver was higher than that in liver tissue, and the content of ￣(3)H-DHAQ-PBCA-NS in annpit tumor was higher than that in armpit muscle tissue,but had no significant difference;It provides an ideal preparation for the DHAQ admini-stration.

Metastatic human hepatocellular carcinoma models in nude mice and cell line with metastatic potential

Metastatic human HCC model is needed for the studies on mechanism and intervention of metastatic recurrence. By using orthotopic implantation of histologically intact tissues of 30 surgical specimens, a patient-like metastatic model of human HCC in nude mice (LCI-D20) and a low metastatic model of human HCC in nude mice (LCI-D35) have been established. All mice with transplanted LCI-D20 tumors exhibited extremely high metastatic ability including spontaneous metastasis to liver, lungs, lymph nodes and peritoneal seeding. Remarkable difference was also found in expression of some of the invasiveness related genes and growth factors between the LCI-D20 and LCI-D35 tumors. PAI-1 increased gradually following tumor progression in LCI-D20 model, and correlated with tumor size and AFP level. Phasic expression of tissue intercellular adhesion molecule-1 in this model was also observed. Using corneal micropocket model, it was demonstrated that the vascular response induced by LCI-D20 tumor was stronger than that induced by LCI-D35 tumor. Similar report on metastatic human HCC model in nude mice and human HCC cell line with metastatic potential was rarely found in the literature. This LCI-D20 model has been widely used for the studies on intervention of metastasis, including anti-angiogenesis,antisense approach, metalloproteinase inhibitor, differentiation inducer, etc. It is concluded that the establishment of metastatic human HCC model in nude mice and human HCC cell line with metastatic potential will provide important models for the in vitro and in vitro study of HCC invasiveness, angiogenesis as well as intervention of HCC recurrence.

Microencapsulated tumor assay:Evaluation of the nude mouse model of pancreatic cancer

AIM: To establish a more stable and accurate nude mouse model of pancreatic cancer using cancer cell microencapsulation. METHODS: The assay is based on microencapsulation technology, wherein human tumor cells are encapsulated in small microcapsules (approximately 420 μm in diameter) constructed of semipermeable membranes. We implemented two kinds of subcutaneous implantation models in nude mice using the injection of single tumor cells and encapsulated pancreatic tumor cells. The size of subcutaneously implanted tumors was observed ona weekly basis using two methods, and growth curves were generated from these data. The growth and metastasis of orthotopically injected single tumor cells and encapsulated pancreatic tumor cells were evaluated at four and eight weeks postimplantation by positron emission tomography-computed tomography scan and necropsy. The pancreatic tumor samples obtained from each method were then sent for pathological examination. We evaluated differences in the rates of tumor incidence and the presence of metastasis and variations in tumor volume and tumor weight in the cancer microcapsules vs single-cell suspensions. RESULTS: Sequential in vitro observations of the microcapsules showed that the cancer cells in microcapsules proliferated well and formed spheroids at days 4 to 6. Further in vitro culture resulted in bursting of the membrane of the microcapsules and cells deviated outward and continued to grow in flasks. The optimum injection time was found to be 5 d after tumor encapsulation. In the subcutaneous implantation model, there were no significant differences in terms of tumor volume between the encapsulated pancreatic tumor cells and cells alone and rate of tumor incidence. There was a significant difference in the rate of successful im- plantation between the cancer cell microencapsulation group and the single tumor-cell suspension group (100% vs 71.43%, respectively, P = 0.0489) in the orthotropic implantation model. The former method displayed an obvious advantage in tumor mass (4th wk: 0.0461 ± 0.0399 vs 0.0313 ± 0.021, t = -0.81, P = 0.4379; 8th wk: 0.1284 ± 0.0284 vs 0.0943 ± 0.0571, t = -2.28, respectively, P = 0.0457) compared with the latter in the orthotopic implantation model. CONCLUSION: Encapsulation of pancreatic tumor cells is a reliable method for establishing a pancreatic tumor animal model.

Translational pancreatic cancer research:a comparative study on patient-derived xenograft models

AIM To assess the viability of orthotopic and heterotopic patient-derived pancreatic cancer xenografts implanted into nude mice.METHODS This study presents a prospective experimental analytical follow-up of the development of tumours in mice upon implantation of human pancreatic adenocarcinoma samples. Specimens were obtained surgically from patients with a pathological diagnosis of pancreatic adenocarcinoma. Tumour samples from pancreatic cancer patients were transplanted into nude mice in three different locations(intraperitoneal, subcutaneous and pancreatic). Histological analysis(haematoxylin-eosin and Masson's trichrome staining) and immunohistochemical assessment of apoptosis(TUNEL), proliferation(Ki-67), angiogenesis(CD31) and fibrogenesis(α-SMA) were performed. When a tumour xenograft reached the target size, it was reimplanted in a new nude mouse. Three sequential tumour xenograft generations were generated(F1, F2 and F3).RESULTS The overall tumour engraftment rate was 61.1%. The subcutaneous model was most effective in terms of tissue growth(69.9%), followed by intraperitoneal(57.6%) and pancreatic(55%) models. Tumour development was faster in the subcutaneous model(17.7 ± 2.6 wk) compared with the pancreatic(23.1 ± 2.3 wk) and intraperitoneal(25.0 ± 2.7 wk) models(P = 0.064). There was a progressive increase in the tumour engraftment rate over successive generations for all three models(F1 28.1% vs F2 71.4% vs F3 80.9%, P < 0.001). There were no significant differences in tumour xenograft differentiation and cell proliferation between human samples and the three experimental models among the sequential generations of tumour xenografts. However, a progressive decrease in fibrosis, fibrogenesis, tumour vascularisation and apoptosis was observed in the three experimental models compared with the human samples. All three pancreatic patient-derived xenograft models presented similar histological and immunohistochemical characteristics.CONCLUSION In our experience, the faster development andgreatest number of viable xenografts could make the subcutaneous model the best option for experimentation in pancreatic cancer.

Human prostate cancer heterotransplants： a review on this experimental model

A common model used for preclinical research was in vitro human tumor cell culture. An alternative model was the direct implantation of a unique patient＇s tumor biopsy specimens into immunodeficient host mice. Published data from PubMed （http：//www.ncbi.nlm.nih.gov） and Current Contents Connect databases （http：//thomsonreuters.com/ products_services/science/science_roducts/a-z/current_contents_connect） were reviewed. Prostate cancer （PCa） heterotransplantation was evaluated using histopathology, morphology, cell differentiation, DNA content, tumor marker expression, metastases, tumor kinetics, tumor take rate and tumor vasculature in the first tumor heterotransplant. The heterotransplanted tumor retained the biological properties of the original tumor, such as morphology, degree of differentiation, pathology, secretory activity, expression of tumor markers and human vasculature. Human PCa heterotransplants have considerable experimental advantages over cell culture following xenotransplantation.

人源异种皮下注射移植法建立子宫内膜异位症纤维化裸鼠模型的评价

目的评估人源子宫内膜异位症纤维化裸鼠模型建立的可行性,确定子宫内膜间充质干细胞是否参与诱导子宫内膜异位症纤维化。方法收集人源子宫内膜标本4例,采用皮下注射的方式1∶3移植到12只BABL/c裸鼠体内。记录病灶皮表形态及体积变化,移植后第15天处死裸鼠,观察病灶形态及其与腹壁周围粘连情况,HE染色评判造模结果,Masson染色评定纤维化程度,免疫荧光追踪子宫内膜间充质干细胞在子宫内膜异位症纤维化进程中的作用。结果裸鼠异位病灶体积随时间增长,呈局限性、囊泡样改变,与腹壁粘连紧密,镜下可见子宫内膜样腺体、胶原纤维沉积,造模成功率为83.4%,造模后病灶胶原纤维容积分数显著升高(P<0.01),共聚焦成像提示子宫内膜间充质干细胞(SUSD2^(+))可在体内向肌成纤维细胞(α-SMA^(+))分化。结论人源异种皮下注射移植的方法建立的裸鼠模型符合子宫内膜异位症纤维化的病变特点,操作简单,可行性高,此外体内观察到子宫内膜间充质干细胞参与诱导子宫内膜异位症纤维化形成,为进一步探究其发病机制提供较好的模型参考。

无背景差分超声分子成像诊断前列腺癌的实验研究

目的基于前列腺特异性膜抗原(PSMA)靶向超声纳米泡(PSMA-NB),探讨无背景成像差分超声分子成像用于前列腺癌靶向诊断及定位的可行性。材料与方法构建PSMA-NB及非靶向纳米泡(NB)。细胞层面检测PSMA-NBs对人前列腺肿瘤22RV1细胞(PSMA阳性表达)和PC-3细胞(PSMA阴性表达)的寻靶能力。构建人前列腺肿瘤22RV1细胞(n=5)、PC-3细胞(n=5)荷瘤裸鼠模型(n=10),经鼠尾静脉注入PSMA-NB,行原位爆破,采集爆破前后的超声分子图像,利用破坏-补充后处理技术,获取并对比两组差分超声分子成像效果。结果PSMA-NB与NB的粒径大小分别为(363.7±24.4)nm、(236.0±55.2)nm,差异有统计学意义(t=3.19,P=0.007)。细胞寻靶结果显示,PSMA-NB仅黏附在PSMA阳性表达的细胞核周围。动物实验提示,PSMA阳性表达组的差分超声分子图像仅在肿瘤部位显示造影剂高增强区域,且无背景噪声。结论基于PSMA靶向超声纳米泡构建的无背景差分超声分子图像可用于精准靶向诊断及定位PSMA阳性前列腺癌。

Incubation and application of transgenic green fluorescent nude mice in visualization studies on glioma tissue remodeling

Background The primary reasons for local recurrence and therapeutic failure in the treatment of malignant gliomas are the invasion and interactions of tumor cells with surrounding normal brain cells. However, these tumor cells are hard to be visualized directly in histopathological preparations, or in experimental glioma models. Therefore, we developed an experimental human dual-color in vivo glioma model, which made tracking solitary invasive glioma cells possible, for the purpose of visualizing the interactions between red fluorescence labeled human glioma cells and host brain cells. This may offer references for further studying the roles of tumor microenvironment during glioma tissue remodeling. Methods Transgenic female C57BL/6 mice expressing enhanced green fluorescent protein （EGFP） were crossed with male Balb/c nude mice. Then sib mating was allowed to occur continuously in order to establish an inbred nude mice strain with 50% of their offspring that are EGFP positive. Human glioma cell lines U87-MG and SU3 were transfected with red fluorescent protein （RFP） gene, and a rat C6 glioma cell line was stained directly with CM-Dil, to establish three glioma cell lines emitting red fluorescence （SU3-RFP, U87-RFP, and C6-CM-Dil）. Red fluorescence tumor cells were inoculated via intra-cerebral injection into caudate nucleus of the EGFP nude mice. Tumor-bearing mice were sacrificed when their clinical symptoms appeared, and the whole brain was harvested and snap frozen for further analysis. Confocal laser scanning microscopy was performed to monitor the mutual interactions between tumor cells and host brain cells. Results Almost all the essential tissues of the established EGFP athymic Balb/c nude mice, except hair and erythrocytes, fluoresced green under excitation using a blue light-emitting flashlight with a central peak of 470 nm, approximately 50% of the offsprings were nu/nu EGFP＋. SU3-RFP, U87-RFP, and C6-CM-Dil almost 100% expressed red fluorescence under the fluorescence microscope. Under fluorescence microscopic view, RFP＋ cells were observed growing wherever they arrived at, locating in the brain parenchyma, ventricles, and para-vascular region. The interactions between the transplanted tumor cells and host adjacent cells could be classified into three types： （1） interweaving; （2） mergence; and （3） fusion. Interweaving was observed in the early stage of tumor remodeling, in which both transplantable tumor cells and host cells were observed scattered in the tumor invading and spreading area without organic connections. Mergence was defined as mutual interactions between tumor cells and host stroma during tumorigenesis. Direct cell fusion between transplantable tumor cells and host cells could be observed occasionally. Conclusions This study showed that self-established EGFP athymic nude mice offered the possibility of visualizing tumorigenesis of human xenograft tumor, and the dual-color xenograft glioma model was of considerable utility in studying the process of tumor remodeling. Based on this platform, mutual interactions between glioma cells and host tissues could be observed directly to further elucidate the development of tumor microenvironment.

以丙型肝炎病毒体内感染裸鼠模型筛选20种常用清热解毒类中药

目的:用HCV体内感染裸鼠模型筛选20种常用清热解毒类中药,以寻找有效的抗HCV药物。方法:模型鼠用药3个月,用透射电子显微镜观察裸鼠脾内移植的人胎肝细胞中是否仍有HCV样颗粒,用定量RT-PCR技术检测用药前后血清HCVRNA含量。结果:(1)各中药组,用药3个月在裸鼠脾脏内移植的人胎肝细胞中均可找到HCV样颗粒。(2)仅龙胆草、黄芩、山豆根、栀子、苦参5味中药组,用药3个月后血清HCVRNA含量明显下降,其他中药组,用药3个月前后血清HCVRNA含量无明显下降。结论:该20种中药均无直接清除HCV的作用,但龙胆草、黄芩、山豆根、栀子及苦参5味中药可明显抑制HCVRNA的复制。

Avastin对胃癌裸鼠原位移植模型血管生成的影响

背景与目的:血管内皮生长因子(vascularendothelialgrowthfactor,VEGF)和肿瘤的生长和转移密切相关,本实验通过VEGF单克隆抗体Avastin联合或不联合氟尿嘧啶(5-fluorouracil,5-FU),对人类胃癌裸鼠原位种植模型的肿瘤生长和转移进行干预治疗,从而探讨Avastin对胃癌生长、转移和血管生成的抑制作用。方法:应用原位移植方法建立裸鼠胃癌转移模型,术后10天将裸鼠随机分为4组:对照组、5-FU单药组、Avastin单药组和联合用药组。经过6周的治疗,对裸鼠原位肿瘤的瘤重、抑瘤率、肿瘤微血管密度、凋亡指数以及肝脏转移灶进行检测和分析。结果:和对照组相比,5-FU单药组、Avastin单药组和联合用药组原位移植肿瘤重量明显降低,抑瘤率分别为37.52%,58.76%和98.51%。微血管密度Avastin单药组和联合用药组均比对照组明显减少(8.40±1.26和7.20±1.23vs15.30±1.06),而5-FU组与对照组之间没有显著的差别;Avastin单药组和联合用药组的凋亡指数比对照组明显升高[(11.50±1.58)%和(13.60±1.35)%vs(4.70±1.70)%]。联合应用Avastin和5-FU对肝脏转移灶具有明显的抑制作用,而其他3组的抑制肝转移效果没有明显的差别。结论:抗VEGF抗体Avastin通过抑制肿瘤新生血管的生成而诱导胃癌细胞凋亡,进而显著抑制裸鼠原位肿瘤的生长。联合应用Avastin和5-FU不仅对原位肿瘤的生长抑制最为明显,而且对肝脏转移有显著的抑制作用。因此,联合应用Avastin和传统的细胞毒化疗药物对胃癌的治疗效果更显著。

人卵巢癌裸鼠移植瘤模型的建立及其生物学特性的实验应用研究

研究用１例人卵巢癌淋巴转移的癌组织直接移植于裸鼠皮下，建成一株人卵巢癌移植瘤动物模型，已传至５经２６代。移植成功率达１００％，平均裸带瘤存活中位数为１０２。肿瘤倍增时间为７．１７天。组织学和超微结构形态证实保持了原人肿瘤的特征，有淋巴结转移行为。人类肿瘤染色体特征。保留了分泌癌胚抗原的能力。具有Ｐ５３癌基因蛋白的异常表达。移植瘤细胞可在体外培养并传至５例。流式细胞仪及显微光光度计检测移植瘤。

阳和汤对裸鼠荷人乳腺癌组织中CD90表达的影响及其抑瘤作用

目的:探讨阳和汤对裸鼠荷人乳腺癌组织中CD90表达及其抑瘤作用。方法:将人乳腺癌细胞培养接种于裸鼠第四乳腺脂肪垫,建立裸鼠荷人乳腺癌模型,随机将荷瘤裸鼠分为5组:空白对照组、环磷酰胺组、阳和汤低浓度组、阳和汤中浓度组、阳和汤高浓度组,并于接种后14 d给药2周,给药结束后24 h麻醉,拉颈处死裸鼠,剥离肿瘤组织,称取瘤质量并绘制瘤体生长曲线、计算抑瘤率及采用免疫组化法测定组织中CD90的表达。结果:1)环磷酰胺组及阳和汤组CD90表达均低于空白对照组,差异有统计学意义(P<0.05),而环磷酰胺组与阳和汤组比较差异无统计学意义(P>0.05),环磷酰胺组、阳和汤低浓度组、阳和汤中浓度组、阳和汤高浓度组的表达阳性率均数分别为0.34%、0.73%、0.52%及0.42%;2)环磷酰胺组及阳和汤组肿瘤体积及瘤质量均小于空白对照组,差异有统计学意义(P<0.05),而环磷酰胺组与阳和汤组比较差异无统计学意义(P>0.05),环磷酰胺组、阳和汤低浓度组、阳和汤中浓度组、阳和汤高浓度组的抑瘤率分别为63.64%、37.45%、47.64%及63.27%。结论:1)阳和汤对人乳腺癌组织中CD90表达具有明显下调作用,可能是其抑制乳腺癌的作用机制之一;2)对人乳腺癌细胞的生长具有明显抑制作用。

VEGF在人子宫内膜异位症裸鼠模型组织中的表达及意义

目的建立人子宫内膜异位症(EMs)裸鼠模型,检测血管内皮生长因子(VEGF)在正常在位内膜及裸鼠异位内膜的表达,探讨其在EMs发生发展中的作用。方法分别采用皮下种植和腹腔注射的方法,建立EMs裸鼠模型,光镜下观察异位病灶的形态学特点,并采用免疫组化法检测正常在位内膜及裸鼠异位内膜中VEGF蛋白表达水平。结果实验裸鼠共20只,皮下种植组10只,8只成模,腹腔注射组10只,7只成模,异位病灶在光镜下呈现增生期特点;正常在位内膜10例,VEGF蛋白在异位内膜中的表达有增多趋势(t=2.632,P<0.05)。结论成功建立人EMs裸鼠皮下种植及腹腔注射模型,检测到VEGF表达较正常在位内膜增多,该模型可用于进行人EMs血管生成及抗血管生成治疗的研究模型。

ErbB2高表达的人乳腺癌原位移植瘤裸鼠模型的建立

目的采用人乳腺癌细胞株BT-474建立稳定高表达ErbB2的人乳腺癌裸鼠移植瘤模型,选择合适的模型制作方法。方法实验前1d在36只裸鼠颈部皮下埋植0.5mg17β雌二醇缓释片,并随机分为3组:原位组将5×106个BT-474细胞接种于裸鼠左侧第二乳房垫内,胁部皮下组将同样数量的BT-474细胞接种于裸鼠左侧胁部皮下,腋窝组则接种于裸鼠左侧腋窝内;观察3组裸鼠荷瘤情况及移植瘤病理组织学特点,并采用免疫组化方法动态监测移植瘤的ErbB2表达情况。结果 3组裸鼠的荷瘤率均为100%,都保持了原发肿瘤高表达ErbB2的特点;和两组对照相比,原位组肿瘤形状、生长速度及细胞增殖与血管生成等生物学特征一致性更强;此外,原位组的肿瘤对治疗药物处理也有良好反应。结论 BT-474细胞接种于乳房垫内比胁部皮下及腋窝建立的裸鼠移植瘤模型更适于进行抗ErbB2抗体等药物的药理学研究。

子宫内膜异位症裸鼠模型子宫内膜的雌、孕激素受体表达

目的:建立子宫内膜异位症裸鼠模型,观察子宫内膜的雌激素受体(ERs)、孕激素受体(PRs)及其亚型的表达情况,为进一步探讨内异症子宫内膜孕激素抵抗的发生机制提供研究模型。方法:建立子宫内膜异位症裸鼠模型,分别于造模后1月、2月、3月取裸鼠子宫内膜,利用RT-qPCR和Western blot法检测其孕激素受体(PRA、PRB)和雌激素受体(ERα、ERβ)表达情况。结果:与对照组相比,内异症组裸鼠内膜的PRB和ERα表达降低,在造模后3月最明显;PR和ERβ表达升高,PRB/PRA和ERα/ERβ比值降低,均在造模后3月最明显。结论:子宫内膜异位症裸鼠模型是研究内异症的理想模型之一,造模后的裸鼠内膜存在孕激素抵抗。

人乳腺癌裸鼠移植模型的建立

目的 :建立人乳腺癌裸鼠移植模型 ,并探讨其部分生物学特性。方法 :采用雌激素受体阳性的 MCF- 7人乳腺癌细胞株 ,接种于 2 0只裸小鼠右侧胸壁乳垫下 ,移植细胞总数为 1× 10 6 /只。观察肿块生长情况 ,至 90天处死荷瘤鼠 ,切除肿块作病理切片 ,角蛋白19( KT19) m RNA、雌激素受体 ( ER)检测。结果 :接种后第 10天在接种部位可见结节 ,肿瘤移植成功率 (成瘤率 )为 95 %( 19/2 0 )。切除肿块平均直径为 ( 14± 3 ) mm,平均重量为 1.4 g,病理学检查为浸润性导管癌 ,RT- PCR检测表达人角蛋白 19( KT19)、ER阳性。结论 :该方法建立的人乳腺癌裸鼠移植模型 ,成功率高 ,肿瘤可部分保持人乳腺癌生物学特性 。

人结肠癌裸鼠原位移植瘤模型的建立

目的建立人结肠癌裸鼠原位移植瘤模型。方法使用对数生长期的人结肠癌细胞(lovo)在8只裸鼠结肠浆膜至黏膜逐层注射,以完成原位移植瘤模型的制备,同时皮下种植8只裸鼠作为对照组。分别于第4、6、8、12周各组分别处死裸鼠2只,观察原位种植肿瘤的成瘤率、生长情况、转移率和腹水出现率。结果16只裸鼠实验期间无1只死亡,成瘤率为100%,原位种植成瘤率为100%(8/8),区域淋巴结转移率100%(8/8),肝转移率为100%(8/8),肺脏转移率为75.0%(6/8),腹膜转移率为75.0%(6/8),腹水出现率为27.5%(3/8)。皮下种植组未见转移。结论本实验成功建立了人结肠癌裸鼠原位移植瘤模型,该模型的生物学行为与临床病程非常相似,为研究人结肠癌转移机制和干预措施提供了较为理想的动物模型。

人卵巢癌裸鼠移植实体瘤模型的建立

目的建立人卵巢癌裸鼠移植实体瘤模型。方法将1例人卵巢癌组织移植裸鼠,建立人卵巢癌裸鼠原代移植实体瘤模型的基础上,再将实体瘤皮下移植、实体瘤原位移植、实体瘤细胞移植裸鼠。观察裸鼠实体瘤生长和转移情况,称量其体重、子宫卵巢重、瘤重及瘤的大小,并作病理、电镜、染色体检查。结果成功地建立人卵巢癌裸鼠移植实体瘤模型,并已传至第18代,传代移植成功率100%,组织学和超微结构形态均证明该实体瘤保留了原人卵巢癌特征,有人卵巢癌染色体特征,并出现肝、脾转移。结论本研究建立人卵巢癌裸鼠移植实体瘤模型与人相似,通过18代传代和实验观察方法稳定可靠。为人卵巢癌的研究提供了理想的动物模型。

实验性持续腹腔化疗裸小鼠人卵巢癌腹腔移植瘤

目的 :评价持续腹腔冲洗化疗对人卵巢上皮癌裸鼠腹腔瘤治疗的效果。方法 :首先用裸鼠建立卵巢浆液性上皮癌细胞株SKOV3腹腔瘤动物模型 ,然后分 3组 ,即常规cDDP化疗组 (常规组 )、持续冲洗化疗组 (冲洗组 )和对照组进行腹腔化疗的动物实验。二疗程后处死裸鼠 ,测其体重、腹腔瘤大小 ;流式细胞术 (FCM)检测腹腔冲洗液的细胞周期及凋亡率、瘤组织C erbB2、Fas的表达。结果 :冲洗组的裸鼠末体重 (FBW ) 初体重 (IBW) =0 .886 ,冲洗组腹腔瘤的体积明显小于常规组 ,抑瘤率明显增高 ,差异显著 (P <0 .0 5 )。腹腔冲洗液中G1 期、S期比例明显下降 (P <0 .0 5 ) ,细胞凋亡率明显升高 (P <0 .0 5 ) ,而细胞数无明显下降 (P >0 .0 5 )。C erbB2在常规组、冲洗组和对照组的表达率分别为 5 9%、42 %和 6 6 % ,3组之间比较均具有显著意义 (P <0 .0 5～P <0 .0 1)。Fas凋亡基因在 3组的表达率分别为 2 2 %、2 9%和 13% ,均具有显著意义 (P <0 .0 5～P <0 .0 1)。结论 :腹腔持续冲洗化疗治疗裸鼠腹腔瘤与常规方法相比具有显著疗效 ,且毒性并未有增加的趋势。

三种人卵巢癌动物模型的生物学特性比较

目的:建立人卵巢癌裸小鼠皮下移植瘤,腹水瘤和原位移植瘤模型,观察比较其生物学特性,为卵巢癌的理论研究和选择临床模型选择提供参考。方法:利用卵巢癌细胞株SW626先制备裸小鼠皮下移植瘤模型,再将瘤组织条植入裸小鼠一侧卵巢内,建立人卵巢癌的原位移植模型,将该细胞悬液注入小鼠腹腔建立腹水瘤模型。用组织病理学,电镜和流式细胞仪DNA含量及染色体核型分析鉴定模型,并比较3种模型在生物学特性上的差异。结果:3种模型的瘤细胞与细胞株在形态和结构上一致,腹水瘤模型自然生存率明显短于其它两种模型,后两者无明显差异。在生物学特性上各具特点,其中原位移植瘤模型中肿瘤的生长和转移完全模拟人卵巢癌的临床过程。结论:3种模型从不同层面展现了人卵巢癌的生物学特点,其中原位移植瘤模型是研究卵巢癌的转移基础和评定抗癌药物药效更客现的模型。